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Angiogenesis is considered one of the
hallmarks of tumor initiation and pro-
gression therefore it is also the widely
accepted therapeutic target. It has been
shown that angiogenesis blockers prolong
patient’s survival for several months (1).
In order to progress, cancer cells acquire
several distinct morphological alterations
increasing their capacity to proliferate and
independently sustain growth, and at the
same time, inhibit homeostatic, physio-
logic signals from the microenvironment
they are in, and under the control of which
they should have remained. This is the
main principle behind a tumor gaining the
ability to metastasize (2). Till now, several
agents have been approved by the Food
and Drugs Administration (FDA) but their
efficacy is still limited and this observa-
tion is repeatedly proven by recurrence of
more aggressive tumor after application of
anti-angiogenic therapy (3).
So far stated is highly suggestive to
back up and justify the existence of hyper-
plasia in the field of research for novel
therapies, which would induce suppression
of angiogenesis in carcinogenesis cascade
and limit tumor progression. The com-
plexity of angiogenesis becomes one of
the greatest challenges in understanding
various processes of inflammation, repa-
ration, tumorigenesis, and metastases. In
following paragraphs, we will try to express
opinion where in near future we should
probably search for the next generation
of promising therapeutics for manage-
ment of prostate cancer. It has been estab-
lished that new blood vessel formation is
required for tumor growth (4). The muta-
tions, which predispose tissue to neoan-
giogenesis and induce tissue invasion,
are reactivated genetic programs normally
turned off in adult human especially those
activated during reparation processes in
the surrounding microenvironment, where
pro-angiogenic factors play a key role in
establishing a capillary network from the
surrounding host tissues (5). The sur-
rounding stromal cells, tumor-associated
macrophages, and other components of the
extracellular also actively constitute matrix
chemical milieu, and not just the cancer
cells alone as previously implied. To be
more precise, angiogenic switch by its defi-
nition implies impaired angiogenesis and
importance of high vascular endothelial
growth factor (VEGF) and VEGF recep-
tor (VEGFR) levels holding responsible for
PCA progression (6).
The level of oxygenation in prostate is
important for estimation of its hypoxic
state. Namely, hypoxic state is informative
as relative tissue oxygenation status, which
correlates with overall VEGF expression
in prostate (7–10). Progressive induction
of hypoxia influences metabolic changes
at cellular level in prostate epithelial cells
and their energetic demands are being
modified accordingly. Impaired systems of
cellular repair are not capable to restore
in full sublethal cellular damage induced
by hypoxia therefore pro-inflammatory
cytokines are being increasingly secreted
by prostate gland epithelia. This leads
toward further promotion of immunologic
response inducing chronic inflammation.
From other tumor models it has been
known that long lasting chronic inflamma-
tion stimulates cellular proliferation and
favors fasten growing, which is often in
hypoxic circumstances deranged at certain
level. Oxygen delivery and consumption
are regulated with hypoxia-inducible fac-
tors (HIFs) among other molecules, which
also induce transcription of VEGF stimu-
lating, in turn, tumor angiogenesis due to
increased oxygen demand. Hypoxic can-
cer cells are stimulated to acquire inva-
sive and metastatic properties and they
are promptly developing resistance to
chemotherapy too (11). Although signifi-
cance of inflammation in cancer progres-
sion has been discussed and researched
for a long time, till recently, research has
extrapolated pathways directed to connec-
tion between inflammation and cancer
evolution. Different studies strongly point
out that chronic inflammation is involved
in progression of chronic prostatic dis-
ease, such as benign prostatic hyperpla-
sia (BPH) and consequent development
of prostate cancer (12). The coincidence
of chronic inflammation and tumorigen-
esis in the peripheral zone identified as
so-called proliferative inflammatory atro-
phy is proposed as possible precursor of
prostatic intraepithelial neoplasm. This can
be explained since inflammatory microen-
vironment releases growth factors and
cytokines that may influence the activa-
tion of the vascular endothelial cells and
signal transduction in these cells. Con-
tinuous inflammatory stimuli as it have
been previously shown result in endothelial
sprouting. This links process of inflam-
mation with angiogenesis, which predis-
poses preexisting endothelial cells to con-
tinuous activation and usually has its gene
activation for consequence. Neovascular-
ization includes also presence of dysfunc-
tional endothelial cells, which is partic-
ularly present during chronic inflamma-
tion and among others related with sus-
tained p38 MAP kinase pathway activ-
ity and increased levels of migration of
cytokines. When observed, described gene
changes reactive oxygen species (ROS)
levels are elevated (13). The novel fac-
tors could possibly influence angiogenic
www.frontiersin.org September 2014 | Volume 4 | Article 243 | 1
Štifter and Ðord¯evic´ Angiogenic switch and prostate cancer
switch consequently leading to progres-
sion from low-grade prostatic intraepithe-
lial neoplasia (PIN) to high-grade PIN
and beyond to prostate cancer or even
more aggressive, poorly differentiated, and
androgen-independent histological sub-
types.
From morphological point of view, it
is important to recognize the presence
of even small amount of microscopic
patterns, which may be responsible for
prompt tumor progression, advancement,
and transition from low-grade lesion to the
high grade one.
Today, we are aware of their importance
and connection with different molecular
pathways, which prevail in interplay among
tumor cells and environment interaction.
Recently, it has been shown that the p38-
MAPK pathway can be activated under
continuous extensive anti-androgen expo-
sure in prostatic cancer cells, and that the
p38-MAPK pathway has a critical role in
the induction of resistance, as well as in
the acquisition of a more aggressive and
invasive phenotype (13). This observation
is at least interesting if we would not exag-
gerate since it offers potentially new thera-
peutic escape window. Namely, proposed
role of p38 in controlling the phospho-
rylation and activity of transcription fac-
tors that has been established would regu-
late tumor and stromal cells proliferation
and the expression and release of mul-
tiple tumor-derived cytokines. Cytokines
may in turn promote tumor angiogenesis
and lymphangiogenesis, thereby favoring
the establishment of a permissive tumor
microenvironment. The prostate microen-
vironment appears relatively simple in
comparison with some other milieus (i.e.,
bone marrow for instance) since it consists
of the components of supporting stromal
elements’ extracellular matrices, and pre-
dominantly, carcinoma-associated fibrob-
lasts. Activation and increased expres-
sion of several adhesion molecules cor-
relate with a progression of malignant
tumors. CD44 has been recognized to
recruit and accumulate matrix metallopro-
teinase on the cell surface, enabling indi-
rectly tumor cell angiogenesis and inva-
sion (14). CD44 is also recognized as
a potential target for cells gained pre-
metastatic phenotype and entering process
of epithelial–mesenchimal transition (15).
Understanding a different expression of
CD44s marks and metalloproteinase in
the field of invasion may help in rec-
ognizing patients with more aggressive
forms of prostate tumors, who should be
treated surgically and also additionally.
Fibroblast actively participates in extra-
cellular matrix remodeling thereby pro-
moting actively carcinogenesis and stim-
ulating prostate cancer cell proliferation
and angiogenesis (15, 16). From this con-
cept, two options of therapeutic actions are
deriving one targeting reactive stroma and
other is aiming inflammatory, stromal and
circulating cells (17). There is a constant
need of new anticancer agents, in general
oncologic therapy. Though exact molec-
ular events enabling prostate cell malig-
nant transformation and the ability to gain
aggressive metastatic phenotype remain
elusive, it is important not to overlook the
importance that new therapeutic agents
should be able to provide a therapeu-
tic solution for both local and metastatic
prostate cancer. As previously mentioned,
as agents capable of disrupting MAPK sig-
naling pathway and inducing irreversible
inhibition of tumor proliferation, angio-
genesis and metastatic potential, and as
moderators of expression and function
of adhesion molecules, molecule CD44
would probably be the next generation of
promising therapeutics for management of
prostate cancer.
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